Live feed08:03:00·17mPRReleasevia QuantisnowNew Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitisByQuantisnow·Wall Street's wire, on your screen.LLY· Eli Lilly and CompanyHealth Care
